Revenue missed consensus by ~21%, but the miss is likely due to the consensus being stale or misaligned with quarterly cadence. The FY guidance of >$1B (including $40M Regeneron payment) implies H2 acceleration. Watch for FDA decisions on Pixclara (PDUFA Sept 11, 2026) and Zircaix BLA resubmission. The $600M convertible refinancing removes near-term debt overhang. The Regeneron deal provides non-dilutive capital and validates platform technology.
Drugs in focus
TLX drug pipeline →TLX591-Tx
● Neutral Named in this press release- Impact
- Phase
- Phase 3
- Time to market
- Likely 2028+ (Phase 3 Part 2 enrollment underway, followed by event-driven rPFS readout, then regulatory filing)
- Next catalyst
- None dated
What to watchWatch for enrollment completion updates on ProstACT Global Part 2 and any interim rPFS data. The stock is heavily influenced by Illuccix/Gozellix revenue execution, so TLX591-Tx is a pipeline upside option, not the core thesis today. Near-term catalysts center on Telix's imaging franchise (Pixclara PDUFA) rather than this therapeutic.
- ● Zircaix 4/10 Phase 3 (ZIRCON) completed; BLA under FDA review Named in filing
- ▲ Gozellix 3/10 Approved (FDA, March 21, 2025 — NDA 219592, 505(b)(2)) Named in filing
- ● TLX101-Tx 3/10 Phase 3 (pivotal, just initiated); Phase 1 safety stage complete Named in filing
- ◆ ITM-11 4/10 Phase 3 (completed)
- All TLX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK AT ENTRY AT T+60- T+0 · Jul 21 $10.92entry
- T+1 · 4mo ago −5.49%α −5.38% · $10.32
- T+5 · 4mo ago −8.61%α −7.38% · $9.98
- T+20 · 3mo ago +8.79%α +6.23% · $11.88
- T+60 · 5w ago 0.00%α −3.97% · $10.92
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Telix reported Q2 2026 revenue of $247M, up 21% YoY and 7% QoQ, driven by Precision Medicine growth. The company expects FY 2026 revenue and other income to exceed $1B, tracking the upper end of guidance. R&D guidance was raised to $230-270M to accelerate pipeline programs, and a $600M convertible bond refinancing was completed.
Key Financial Metrics
Key Facts
- Q2 2026 revenue $247M, up 21% YoY and 7% QoQ
- Precision Medicine revenue $202M, up 30% YoY and 9% QoQ
- FY 2026 revenue guidance tracking upper end of $950M-$970M, plus $40M non-refundable Regeneron payment
- R&D expenditure guidance raised to $230M-$270M
- Completed $600M convertible bond refinancing, extending maturities to 2031
- FDA alignment on ProstACT Global Phase 3 trial for TLX591-Tx in mCRPC
- Regeneron strategic collaboration for next-gen radiopharmaceutical therapies
- Three new Non-Executive Directors appointed
Financial Impact
Q2 revenue $247M vs consensus $311.6M (miss), but FY guidance raised to >$1B including $40M Regeneron payment; R&D spend increased by $40-80M
Risk Factors
- Revenue miss vs consensus may pressure near-term sentiment
- R&D spend increase to $230-270M could pressure margins
- Regulatory risk: FDA decisions on Pixclara, Zircaix, and TLX591-Tx IND
- Convertible bond refinancing adds $600M debt, though at longer maturity
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3330166 |
Track record
27 reports on TLX
10 of 20 bullish or bearish reports moved the stock their way by T+1. Best: +29.26% at T+20 after the Jun 1, 2026 report. 18 of 20 went positive at some point.
Filters
- Oct 29, 202618d ago 6-K Neutral 5/10 Entry $9.10 to $9.05 Now $8.92 −1.98% ▼ −0.55% −0.07% vs SPY
- Oct 20, 202627d ago 6-K Neutral 4/10 No price data
- Oct 20, 202627d ago Press Release Bullish 6/10 Entry $10.03 to $9.54 Now $8.92 −11.07% ▼ −4.89% −3.70% vs SPY
- Sep 29, 20266w ago 6-K Bullish 6/10 Entry $10.97 to $10.72 Now $8.92 −18.69% ▼ −2.28% −2.46% vs SPY
- Sep 21, 20268w ago 6-K Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 20, 20268w ago Press Release Bullish 7/10 Entry $11.31 to $11.95 Now $8.92 −21.13% ▲ +5.66% +5.67% vs SPY
- Sep 14, 20269w ago 6-K Bullish 8/10 Entry $12.83 to $11.83 Now $8.92 −30.48% ▼ −7.79% −7.35% vs SPY
- Sep 14, 20269w ago Press Release Bullish 8/10 Entry $11.78 to $12.83 Now $8.92 −24.28% ▲ +8.91% +9.37% vs SPY
- Sep 1, 202610w ago 6-K Bullish 7/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
- Sep 1, 202610w ago Press Release Bullish 6/10 Entry $11.45 to $11.74 Now $8.92 −22.10% ▲ +2.53% +1.49% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers